Narrowing the knowledge gap in atypical HUS
Open Access
- 19 October 2023
- journal article
- editorial
- Published by American Society of Hematology in Blood
- Vol. 142 (16) , 1334-1335
Abstract
In this issue of Blood, Brocklebank et al1 present the largest single-center cohort with suspected complement-associated atypical hemolytic uremic syndrome (CaHKeywords
This publication has 6 references indexed in Scilit:
- Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort studyBlood, 2023
- Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS StudyKidney International Reports, 2022
- Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter studyBlood, 2021
- Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndromeBlood Advances, 2021
- An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic SyndromeAmerican Journal of Kidney Diseases, 2019
- Discontinuation of Eculizumab Treatment in Atypical Hemolytic Uremic Syndrome: An UpdateAmerican Journal of Kidney Diseases, 2015